NEW YORK, Nov. 25 (GenomeWeb News) - Harvard Bioscience has acquired certain assets of Amersham Biosciences' one-dimensional electrophoresis business, including the Hoefer brand name, for approximately $5.3 million in cash.
Harvard Bioscience has the rights to apply the Hoefer brand across its offerings, including its existing lines of electrophoresis products. Hugh Douglas, who has been with the Hoefer product line since 1979, will manage the Hoefer business for Harvard Bioscience, and will report to David Parr, managing director of Harvard Bioscience's Biochrom business.
Amersham Biosciences will retain its two-dimensional electrophoresis product lines, which include the Multiphor, IPGPhor, and DALT systems and consumables. These products will be sold under the Amersham Biosciences brand.
Harvard Bioscience and Amersham Biosciences have also entered into a long-term, global distribution agreement for at least five years with an option to renew longer-term, under which Amersham Biosciences will continue to distribute and support one-dimensional electrophoresis products manufactured by Harvard Bioscience under the Amersham Biosciences brand. Additionally, Harvard Bioscience will develop new products for Amersham Biosciences, with Amersham Biosciences committing to certain purchase volumes during the first three years.
"This agreement enables us to focus our proteomics area on sample preparation, protein expression, and protein identification as part of the Ettan design for integrated, high-throughput proteomics," said Andrew Carr, president of discovery systems for Amersham Biosciences, in a statement.